EHA 2024 | Insights into real-world outpatient administration of axi-cel and brexu-cel in R/R NHL
Radhika Bansal, MBBS, Mayo Clinic, Rochester, MN, discusses the real-world outpatient administration of axicabtagene ciloleucel (axi-cel) and brexucabtagene autoleucel (brexu-cel) in relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). 155 patients received axi-cel or brexu-cel at Mayo Clinic between 2018 and 2022, with 90% of administrations conducted on an outpatient basis. The study found no increased adverse events such as cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). Early management interventions led to lower CRS rates and hospital stays. This data demonstrates the feasibility and safety of outpatient administration for these agents in clinical practice. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
